Get Involved

This country profile provides an overview of Mali’s progress in reaching those in need of mass NTD treatment based on 2019 data.

*This includes all countries in Africa that are endemic for at least one of the five NTDs

In 2019, insecurity in the north of Mali prevented TAS1 and MDA being conducted for elephantiasis (lymphatic filariasis), which resulted in a low 2019 index score. In 2020, Mali’s NTD programme successfully conducted the relevant surveys and Mali’s score is expected to increase.

Treatment coverage

Elephantiasis
0%
Blinding trachoma
N/A
Intestinal worms
N/A
Bilharzia
95%
River blindness
79%
6.66 million people received treatment in Mali in 2019 1.08 million people did not receive treatment in Mali in 2019

Elephantiasis

Treatment coverage decreased from 69% in 2018 to 0% in 2019.

People needing treatment
1m
People receiving treatment
Zero

Blinding trachoma

Mali is conducting post-preventive chemotherapy surveillance.

Intestinal worms

Mali does not require mass treatment for intestinal worms.

Bilharzia

Treatment coverage increased from 91% in 2018 to 95% in 2019.

School-aged children needing treatment
3.46m
School-aged children receiving treatment
3.3m

River blindness

Treatment coverage increased from 77% in 2018 to 79% in 2019.

People needing treatment
6.11m
People receiving treatment
4.85m

The ESPEN portal (a World Health Organization AFRO region project) provides maps and district-level data for the preventive chemotherapy diseases in Mali.